公开(公告)号：US20240182477A1

公开(公告)日：2024-06-06

申请号：US18472147

申请日：2023-09-21

Applicant: AMGEN INC. ,  VIGIL NEUROSCIENCE, INC.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

CPC classification number: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20230144581A1

公开(公告)日：2023-05-11

申请号：US18072497

申请日：2022-11-30

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20240124446A1

公开(公告)日：2024-04-18

申请号：US18309281

申请日：2023-04-28

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20230002390A1

公开(公告)日：2023-01-05

申请号：US17302502

申请日：2021-05-04

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20190167682A1

公开(公告)日：2019-06-06

申请号：US16319783

申请日：2017-07-20

Applicant: AMGEN INC.

Inventor： Matthew WEISS ,  John R. BUTLER ,  Benjamin Charles MILGRAM ,  Gwenaella RESCOURIO ,  Alessandro BOEZIO ,  Brian Andrew SPARLING ,  Daniel LA

IPC: A61K31/506 ,  A61P25/00 ,  A61K31/4439

CPC classification number: A61K31/506 ,  A61K31/4439 ,  A61P25/00 ,  C07D213/75 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

公开(公告)号：US20230295169A1

公开(公告)日：2023-09-21

申请号：US18072501

申请日：2022-11-30

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20240190863A1

公开(公告)日：2024-06-13

申请号：US17923160

申请日：2021-05-04

Applicant: AMGEN INC. ,  VIGIL NEUROSCIENCE, INC.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/14 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/14 ,  C07D519/00

Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

公开(公告)号：US20210047344A1

公开(公告)日：2021-02-18

申请号：US16977527

申请日：2019-03-04

Applicant: AMGEN INC.

Inventor： Gwenaella RESCOURIO ,  Ana GONZALEZ BUENROSTRO ,  Sean P. BROWN ,  Mike LIZARZABURU ,  Julio MEDINA ,  Salman Yojiro JABRI ,  Daqing SUN ,  Scott Preston SIMONOVICH ,  Xuelei YAN ,  Yihong LI ,  Yosup REW

IPC: C07D498/10 ,  C07D498/20 ,  C07D519/00

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.